Authors: Vergara, F.M.F.; Lima, C.H.S.; Henriques, M.G.M.O.; Candea, A.L.P.; Lourenço, M.C.S.; Ferreira, M.L.; Kaiser, C.R.; De Souza, M.V.N.
Source: European Journal of Medicinal Chemistry, v. 44, p. 4954-4959, 2009.
Publisher: Elsevier
Abstract
The present article describes a series of twenty-six N′-[(E)-(monosubstituted-benzylidene)]-2-pyrazinecarbohydrazide (4–29), which were synthesized and evaluated for their cell viabilities in non infected and infected macrophages with Mycobacterium bovis Bacillus Calmette–Guerin (BCG). Afterwards, the non-cytotoxic compounds (4, 6, 8, 15, 21, 23, 24, 27 and 28) were assessed against Mycobacterium tuberculosis ATCC 27294 using the micro plate Alamar Blue assay (MABA) and the activity expressed as the minimum inhibitory concentration (MIC) in μg/mL. The compounds 6, 23, 27 and 28 exhibited a significant activity (50–100 μg/mL) when compared with first line drugs such as pyrazinamide and were not cytotoxic in their respective MIC values.Keywords:Pyrazine; N-Acylhydrazones; Antimycobacterial activity; Drugs Document Type: Research Article DOI: http://dx.doi.org/10.1016/j.ejmech.2009.08.009 Publication date: 1 de Dezembro de 2009
